1468 Peptide vaccination against PD-L1 reduces tumor growth in preclinical models through stimulation of PD-L1-targeting T cells in the tumor microenvironment

• Marco Carretta,
• Souvik Dey,
• Erika Sutanto-Ward,
• James DuHadaway,
• Dema Ghaban,
• Inés Lecoq,
• Alexander J Muller,
• Evelina Martinenaite,
• Preeyam Patel,
• Marion Chapellier,
• Ayako Pedersen,
• Marcos Iglesias,
• Qin Tang,
• Megan Biller,
• Lea Svendsen

Affiliations

Marco Carretta

National Center for Cancer Immunotherapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Souvik Dey

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

Erika Sutanto-Ward

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

James DuHadaway

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

Dema Ghaban

2Lankenau Institute for Medical Research, Wynnewood, PA, USA

Inés Lecoq

National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Alexander J Muller

Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

Evelina Martinenaite

1IO Biotech, Copenhagen, Denmark

Preeyam Patel

IO Biotech, Copenhagen, Denmark

Marion Chapellier

IO Biotech, Copenhagen, Denmark

Ayako Pedersen

IO Biotech, Copenhagen, Denmark

Marcos Iglesias

1IO Biotech, Copenhagen, Denmark

Qin Tang

1IO Biotech, Copenhagen, Denmark

Megan Biller

1IO Biotech, Copenhagen, Denmark

Lea Svendsen

1IO Biotech, Copenhagen, Denmark